Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study

Ingram, John R. ORCID: https://orcid.org/0000-0002-5257-1142, Bates, Janine, Cannings-John, Rebecca ORCID: https://orcid.org/0000-0001-5235-6517, Collier, Fiona, Evans, Judith, Gibbons, Angela, Harris, Ceri, Howells, Laura, Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Howes, Rachel, Leighton, Paul, Riaz, Muhammad ORCID: https://orcid.org/0000-0002-5512-1745, Rodrigues, Jeremy, Stanton, Helen, Thomas, Kim S. and Thomas-Jones, Emma ORCID: https://orcid.org/0000-0001-7716-2786 2024. Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study. British Journal of Dermatology 190 (3) , pp. 382-391. 10.1093/bjd/ljad388

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but rarely offered in the UK. Objectives To describe current UK HS management pathways and influencing factors to inform the design of future randomised controlled trials (RCTs). Methods THESEUS was a non-randomised 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200mg daily; oral clindamycin and rifampicin both 300mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing, and conventional surgery. Primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. Secondary outcomes: proportion of participants selecting each intervention as their final treatment option; proportion who switch treatments; treatment fidelity, and attrition rates. THESEUS was prospectively registered on ISRCTN Registry: ISRCTN69985145. Results The recruitment target of 150 participants was met after 18 months, in July 2021, with two pauses due to the Covid-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36 years, 81% female, 20% non-white, 64% current or ex-smokers, 86% BMI≥25, 68% moderate disease, 19% severe, and 13% mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after three and six months respectively. Concordance with doxycycline was 52% after three months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing respectively after three months. Uptake of conventional surgery was too small to characterise the intervention. Switching treatment was uncommon and there were no serious adverse events. Conclusions THESEUS established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Oxford University Press
ISSN:	0007-0963
Date of First Compliant Deposit:	22 October 2023
Date of Acceptance:	10 October 2023
Last Modified:	25 Mar 2024 14:55
URI:	https://orca.cardiff.ac.uk/id/eprint/163357

Actions (repository staff only)

Edit Item